Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

3.7K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
3.7K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

1.9K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
1.9K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

1.4K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
1.4K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

3.0K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
3.0K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

3.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CEACAM1 expression by immunohistochemistry in B-cell lymphomas and plasma cell myeloma.

American journal of clinical pathology·2026
Same author

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Methylation variability and LINE-1 activation in multiple myeloma.

bioRxiv : the preprint server for biology·2025
Same author

Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements.

Blood cancer discovery·2025
Same author

Expanding the use of T cell receptor beta constant 1 immunohistochemistry in formalin-fixed paraffin-embedded tissues in assessing T cell clonality in mature and immature T cell neoplasms.

Histopathology·2025

Related Experiment Video

Updated: Aug 19, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.4K

Diffuse large B-cell lymphomas, not otherwise specified, and emerging entities.

Joo Y Song1, Stefan Dirnhofer2, Miguel A Piris3

  • 1Department of Pathology, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA, 91010, USA. josong@coh.org.

Virchows Archiv : an International Journal of Pathology
|December 2, 2022
PubMed
Summary
This summary is machine-generated.

Diffuse large B-cell lymphoma (DLBCL) is a common, aggressive non-Hodgkin lymphoma. Recent molecular profiling advances have refined understanding of its subgroups and drivers, informing updated classifications.

Keywords:
ClassificationDiffuse large B-cell lymphomaGenomicsMolecularUpdate

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.8K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.2K

Related Experiment Videos

Last Updated: Aug 19, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.4K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.8K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.2K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, characterized by aggressive behavior and significant heterogeneity.
  • Recent molecular profiling has elucidated key oncogenic drivers and identified distinct molecular subgroups within DLBCL.
  • The 2017 World Health Organization (WHO) classification provided a framework, but ongoing research necessitates further refinement.

Purpose of the Study:

  • To review recent findings in DLBCL genomic abnormalities and phenotypic characteristics.
  • To discuss proposed changes to DLBCL classification based on new research.
  • To provide an updated perspective on DLBCL classification in light of the 2022 International Consensus Classification.

Main Methods:

  • Literature review of molecular profiling studies in DLBCL.
  • Analysis of genomic abnormalities and phenotypic findings.
  • Comparison of 2017 WHO classification with proposed 2022 International Consensus Classification changes.

Main Results:

  • Molecular profiling has identified shared oncogenic mechanisms and distinct subgroups within DLBCL.
  • New genomic and phenotypic data support revisions to the existing DLBCL classification.
  • The 2022 International Consensus Classification incorporates these advancements for a more precise categorization.

Conclusions:

  • Understanding DLBCL heterogeneity through molecular profiling is crucial for accurate diagnosis and treatment.
  • The proposed changes in the 2022 International Consensus Classification reflect significant progress in DLBCL research.
  • Continued investigation into DLBCL biology will further refine classification and therapeutic strategies.